Island Pharmaceuticals Produced First Batch of Galidesivir
The company aims to use the antiviral in emergency programs to address the lack of approved treatments for Bundibugyo virus.
Updated on Oct. 2, 2026 in Biotech
Live Poll
Should companies provide unproven treatments in areas facing active disease outbreaks?
Island Pharmaceuticals has begun GMP manufacturing of the antiviral drug Galidesivir, producing a 5-kilogram batch for use in Uganda. The production is intended for an emergency-use program under the World Health Organization's Monitored Emergency Use of Unregistered and Investigational Interventions (MEURI) framework.
Why it matters
The lack of approved treatments for the Bundibugyo virus has spurred this emergency manufacturing effort following an outbreak that caused over 8,000 cases. By establishing supply now, the company aims to collect necessary clinical, safety, and virological data from patients under a prospective protocol.
Island Pharmaceuticals is manufacturing a 5-kilogram batch of Galidesivir, an antiviral that previously received over US$70 million in U.S. government investment. This effort supports a clinical strategy designed to evaluate the drug's performance against the Bundibugyo virus.
The players
Island Pharmaceuticals
A biopharmaceutical company focused on repurposing existing, clinically tested antivirals to treat infectious diseases.
World Health Organization
The international public health agency managing the MEURI framework for emergency access to experimental drugs.
The details
Manufacturing is conducted under the WHO MEURI framework, which permits the use of experimental medicines for serious diseases when no proven therapy exists. Island Pharmaceuticals intends to gather data to support the FDA Animal Rule pathway, a regulatory mechanism allowing the approval of drugs based on non-human primate studies when human efficacy trials are not feasible. This data will be combined with results from a planned pivotal Marburg virus study in primates scheduled for late 2026.
Timeline
August 27, 2026: The WHO and Africa CDC declared the Ebola outbreak in Uganda officially ended.
September 27, 2026: Total cases reached 8,137 with 3,926 confirmed deaths.
October 1, 2026: Island Pharmaceuticals commenced GMP production of Galidesivir.
October 2026: The company targets the completion of the first 5-kilogram batch.
November 2026: The company targets the production of a second 5-kilogram batch for primate studies.
The Tech Race
Island Pharmaceuticals is aligning its clinical development with the FDA Animal Rule pathway to secure approval where human efficacy testing is restricted. This strategy positions the company to potentially bridge the gap between experimental emergency interventions and established regulatory standards for filovirus treatments.
This production effort creates a mechanism for patients in Uganda to access the antiviral drug under monitored emergency protocols. The timeline for broader availability remains dependent on the success of the prospective data collection and the subsequent regulatory review process.
The takeaway
The development represents a critical attempt to establish a viable therapeutic protocol for Bundibugyo virus disease using the MEURI framework. Investors and public health observers should watch for the results of the pivotal Marburg primate study scheduled for late 2026.
What happens next
Island Pharmaceuticals targets the completion of a second 5-kilogram batch of Galidesivir in November 2026 to facilitate a planned pivotal Marburg virus study in non-human primates.
Further reading
For more on experimental drug development pipelines, see the Biotech section.
Source note: This article includes information reported by Stockhead.
Live Poll
Should companies provide unproven treatments in areas facing active disease outbreaks?
